Life science specialist Thermo Fisher Scientific has collaborated with the Michael J. Fox Foundation (MJFF) to advance proteomics-enabled Parkinson’s precision medicine.
An estimated 10m people worldwide live with Parkinson’s disease. Although the disease is still diagnosed and monitored largely through clinical symptoms, research shows Parkinson’s disease involves multiple biological pathways and distinct patient subtypes. That complexity has made it difficult to develop biomarkers that reliably identify patient groups, track disease progression and support more targeted therapeutic development.
“Parkinson’s disease is incredibly complex and understanding the biological changes that drive its onset and progression requires looking across many layers of biology,” said Dr Samantha Hutten, MJFF’s principal biomarker scientist, Translational Research.
As the field shifts toward biology-driven precision medicine, large scale proteomic datasets are helping researchers better understand disease biology and generate hypotheses that can be tested across cohorts and methods.
Proteomics can help researchers identify patient subtypes, characterise disease progression, uncover biological pathways linked in inflammation, lysosomal function and neuronal stress, and discover candidate biomarkers for future validation. Combining proteomic insights with longitudinal clinical, genetic imaging and other molecular data can help researchers to understand health and disease.
With the trend towards biology-driven precision medicine in mind, the two organisations have expanded the Parkinson’s Precision Medicine Initiative (PPMI) proteomic data resource to aid the global research community. Thermo Fisher has just completed the Olink Explore HT proteomic analysis of about 5,500 research samples from MJFF’s landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data is now in PPMI’s data repository.
By expanding proteomic analyses within the study, including through partners like Olink, we’re creating new opportunities to identify biomarkers and uncover pathways that may lead to earlier diagnosis, better disease monitoring and more targeted therapeutic approaches for people living with Parkinson’s disease,” said Hutten.
Olink, part of Thermo Fisher, enables high throughput, affinity-based proteomic analysis using Proximity Extension Assay (PEA) technology. Olink’s PEA-based platform is a solution for protein biomarker analysis, supporting applications from discovery through translation and population-scale proteogenomics.
By applying Olink technology to deeply characterised PPMI samples, Thermo Fisher is expanding access to MJFF’s dataset. The project creates a large-scale proteomics resource to help researchers study Parkinson’s disease at the protein level and instigate biological signals associated with disease progression, patient heterogeneity and potential biomarker development.
This analysis reflects a larger trend, as proteomics and multi-omics approaches are gaining broader use in neurodegenerative disease research. These methods can reveal dynamic biological changes that may not be captured through genomics or clinical assessment alone.
“Discovery is only the beginning in Parkinson’s research,” said Yan Zhang, president of proteomic sciences at Thermo Fisher. “The next challenge is determining which molecular signals are reproducible, clinically meaningful and useful for advancing Parkinson’s precision medicine. Making these data available to the research community helps put that validation work into motion.”